Amgen Inc. — Q1 2015 Form 10-Q
Business context and reporting period
Unaudited results for the three months ended March 31, 2015, compared with the same period in 2014. Amgen operates in one segment: human therapeutics. Its principal products accounted for 91% of worldwide product sales.
Financial performance
| Metric | Q1 2015 | Q1 2014 | Change |
|---|---|---|---|
| Total revenue | $5.033 billion | $4.521 billion | +11% |
| Product sales | $4.874 billion | $4.356 billion | +12% |
| Operating income | $2.022 billion | $1.364 billion | +48% |
| Net income | $1.623 billion | $1.073 billion | +51% |
| Diluted EPS | $2.11 | $1.40 | +51% |
| Operating cash flow | $1.329 billion | $1.142 billion | +$187 million |
Operating margin was approximately 40.2%, up from 30.2%; net margin was approximately 32.2%, up from 23.7%. Operating expenses fell 5% to $3.011 billion. R&D declined 13% to $894 million, while SG&A was essentially flat at $1.026 billion. The effective tax rate rose to 13.5% from 10.9%.
Growth was led by ENBREL (+13%), XGEVA (+22%), Prolia (+39%), EPOGEN (+16%), Sensipar/Mimpara (+24%) and other products (+30%). Neulasta/NEUPOGEN sales were flat overall; NEUPOGEN declined 15%. U.S. product sales rose 15%, compared with 3% growth in the rest of the world.
Liquidity, debt and capital returns
At March 31, cash, cash equivalents and marketable securities totaled $27.118 billion, versus $27.026 billion at year-end. Cash and cash equivalents alone were $2.864 billion, down from $3.731 billion. Total debt was $30.341 billion, including $500 million current and $29.841 billion long-term, down from $30.715 billion at December 31. Stockholders’ equity was $26.506 billion.
Operating cash flow was $1.329 billion; investing activities used $952 million and financing activities used $1.244 billion. Financing outflows included $599 million of dividends, $464 million of cash share repurchases and a $225 million Onyx-related contingent consideration settlement. The quarterly dividend was $0.79 per share; $3.4 billion remained authorized for repurchases. Management said available funds, operating cash flow and financing access should meet anticipated needs. Approximately $24.6 billion of cash and securities was generated in foreign tax jurisdictions and intended to remain invested abroad.
Changes, outlook and material risks
- Management attributed improved earnings mainly to higher operating income, reflecting product growth and lower expenses. Cost savings from restructuring helped, while new product launch investments partly offset savings.
- The restructuring plan targets 3,500–4,000 staff reductions by year-end 2015, facility closures in Washington and Colorado, and consolidation in Thousand Oaks. Estimated pretax charges remain $935 million–$1.035 billion; $650 million had been incurred through Q1, including $92 million in the quarter. Substantially all remaining actions and costs were expected in the rest of 2015. Net savings were not expected to be significant in 2015.
- No full-year revenue or EPS guidance is stated in the provided filing text. Management estimated 2015 capital spending at approximately $800 million and said it intends to continue dividends and repurchases, subject to business and market conditions.
- Competition and patent exposure are significant: Amgen’s material U.S. patent for EPOGEN was due to expire in May 2015 and for Neulasta in October 2015. FDA approval of Sandoz’s biosimilar filgrastim and pending biosimilar applications could pressure sales. NEUPOGEN already faced short-acting competition.
- Pipeline and regulatory outcomes remain uncertain. FDA advisory committee review of talimogene laherparepvec was scheduled for April 2015, with an FDA action date of October 27, 2015. The company also disclosed suicidal ideation and completed suicides in the brodalumab program; it said available evidence did not suggest a causal association, while noting regulators would assess the benefit-risk profile. Trebananib’s first-line ovarian cancer study was stopped after the monitoring committee judged it unlikely to meet its primary endpoint.
- Legal proceedings include patent, securities and acquisition-related cases. Amgen appealed rulings adverse to it in the Sandoz filgrastim litigation; the remaining patent claims were stayed pending appeal. The company said outcomes of certain proceedings could materially affect results, financial position or cash flows, though it could not estimate potential losses for the described matters.
- Other exposures include foreign-exchange movements, delayed receivable collections from certain Southern European government customers, and product approval, reimbursement and clinical-development risks. Management reported compliance with applicable debt covenants.
Important facts for investors to verify
- Whether sales growth and favorable product mix persist, especially as biosimilar competition and patent expirations affect Neulasta, NEUPOGEN and EPOGEN.
- Whether the restructuring reaches its stated workforce, facility, cost and timing targets, and how launch and R&D investment affect savings.
- Regulatory and clinical developments for talimogene laherparepvec, brodalumab and other pipeline programs, including related contingent consideration.
- Cash generation, capital returns and debt levels, including the location and potential tax cost of foreign-held funds.
- Developments in significant litigation, government customer collections and foreign-currency exposure.